^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ifebemtinib (IN10018)

    i
    Company:
    Boehringer Ingelheim, InxMed
    Drug class:
    FAK inhibitor
    Related drugs:
    Apply
    a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors (NCT06166836)
    Phase 1/2
    InxMed (Shanghai) Co., Ltd.
    Recruiting
    Last update posted :
    01/18/2024
    Initiation :
    10/12/2022
    Primary completion :
    12/31/2025
    Completion :
    12/31/2026
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    garsorasib (D-1553) • ifebemtinib (IN10018)
    IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma (NCT04109456)
    Phase 1
    InxMed (Shanghai) Co., Ltd.
    Recruiting
    Last update posted :
    01/10/2024
    Initiation :
    03/16/2020
    Primary completion :
    06/30/2024
    Completion :
    09/30/2024
    NRAS
    |
    NRAS mutation • NRAS Q61 • NRAS G12 • NRAS G13
    |
    Tecentriq (atezolizumab) • Cotellic (cobimetinib) • ifebemtinib (IN10018)
    Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors (NCT05379946)
    Phase 1/2
    InventisBio Co., Ltd
    Recruiting
    Last update posted :
    10/18/2023
    Initiation :
    10/12/2022
    Primary completion :
    06/30/2024
    Completion :
    12/30/2024
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    garsorasib (D-1553) • ifebemtinib (IN10018)
    IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (NCT06014528)
    Phase 2
    InxMed (Shanghai) Co., Ltd.
    Recruiting
    Last update posted :
    08/28/2023
    Initiation :
    09/06/2022
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    MUC16
    |
    MUC16 elevation
    |
    pegylated liposomal doxorubicin • ifebemtinib (IN10018)
    A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic Cancer (NCT01335269)
    Phase 1
    Boehringer Ingelheim
    Completed
    Last update posted :
    12/09/2015
    Initiation :
    07/01/2011
    Primary completion :
    09/01/2015
    Completion :
    12/01/2015
    CDH1 • PTK2
    |
    CDH1 expression
    |
    ifebemtinib (IN10018)